Bright Minds Biosciences Inc. - common stock — movimiento de fondos (NASDAQ:DRUG)

Financials

Flujo de caja de las actividades operativas ————— — Flujo de caja de las actividades de inversión ————— — Flujo de caja de las actividades financieras ————— — Flujo de caja libre ————— —

Bright Minds Biosciences Inc. - common stock

Bright Minds Biosciences is an American pharmaceutical company which is developing serotonin 5-HT₂ receptor agonists for potential medical use. It has a particular focus on serotonin 5-HT2C receptor agonists, for instance to treat rare epilepsies and other conditions. Another area of focus for the company is serotonergic psychedelics and non-hallucinogenic psychoplastogens. The company was co-founded by Ian McDonald and Gideon Shapiro. The lead scientist at Bright Minds Biosciences was previously Alan Kozikowski. Bright Mind Biosciences was founded in 2017 and its headquarters are in New York City, New York.

DRUG

Financials

Bright Minds Biosciences Inc. - common stock

Noticias

Jefferies inicia cobertura de Bright Minds con compra por fármaco para epilepsia

BTIG reitera calificación de acciones de Bright Minds Biosciences por potencial en tratamiento de convulsiones

H.C. Wainwright eleva el precio objetivo de Bright Minds a 145 dólares tras datos de ensayos

H.C. Wainwright eleva precio objetivo de Bright Minds a $145 por datos

Bright Minds stock price target raised to $145 by H.C. Wainwright on trial data

Bright Minds Biosciences cierra una oferta pública de 175 millones de dólares

Bright Minds Biosciences cierra oferta pública de 175 millones de dólares

Bright Minds Biosciences cierra oferta pública de $175 millones

Bright Minds Biosciences closes $175 million public offering

Bright Minds Biosciences fija precio de oferta pública en $90 por acción

Bright Minds Biosciences fija precio de oferta pública en 90 dólares por acción

Bright Minds Biosciences prices public offering at $90 per share